查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1661108

2025 年至 2033 年生物製藥市場報告，按適應症（自體免疫疾病、腫瘤學、代謝紊亂等）、類別（重組蛋白、單株抗體、純化蛋白）和地區分類

Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2024IMARC Group全球生物製藥市場規模達到 3,262 億美元。慢性病發病率不斷上升、生物製藥的重大進步、政府支持和醫療支出的增加、個人化醫療和標靶治療、生物相似藥的擴張以及人工智慧和機器學習的利用率不斷提高等因素推動了市場的發展。

生物製藥，也稱為生物製劑，是一類源自生物來源的藥物。它們是利用細菌、酵母或哺乳動物細胞等生物體透過生物技術過程生產的。與化學合成的傳統小分子藥物不同，生物製藥是大型複雜分子，與體內的生物標靶表現出高度特異性的相互作用。與傳統藥物相比，它們具有多種優勢。它們的作用往往具有高度特異性，通常針對特定的受體或分子，從而提高療效並減少副作用。此外，生物製藥還有潛力治療以前難以用傳統藥物治療的疾病。

由於個人化醫療需求不斷增加，市場正在經歷顯著成長。此外，生物製藥在治療癌症、糖尿病、牛皮癬和類風濕性關節炎方面的應用越來越廣泛，這也是另一個主要的成長誘導因素。此外，大眾對生物製藥的有效性和可用性的認知不斷提高，這是另一個重要的成長因素。此外，對罕見疾病和孤兒藥的日益關注正在推動市場的成長。這些罕見疾病通常以患者人數少為特徵，存在著巨大的未滿足的醫療需求。除此之外，世界各國政府和監管機構都推出了激勵措施並簡化了監管流程，以鼓勵開發這些疾病的治療方法。此外，生物製藥公司正在投資研發針對罕見疾病的孤兒藥，從而解決關鍵醫療需求並為市場擴張創造機會。

生物製藥市場趨勢/促進因素：

個人化醫療需求不斷成長

個人化醫療已導致生物製藥市場向標靶治療和精準醫療方法的轉變。生物製藥公司越來越注重開發針對特定基因突變、生物標記或與疾病相關的分子路徑的治療方法。此外，個人化醫療推動了藥物基因組學的進步，該學科是研究個人基因組成如何影響其對藥物的反應。了解影響藥物代謝、功效和安全性的基因變異可以識別可能有不良反應風險的患者或更有可能對特定治療產生良好反應的患者。這些知識使生物製藥公司能夠針對個別患者制定針對性的治療方法和給藥方案，從而提高治療效果並降低不良事件的風險。

慢性病和生活方式相關疾病的盛行率不斷上升

慢性疾病，包括心血管疾病、糖尿病、癌症、呼吸系統疾病和自體免疫疾病，已成為全球主要的健康挑戰。這些疾病通常具有複雜的潛在機制，需要有針對性的個人化治療方法。單株抗體、重組蛋白和基因療法等生物製藥可提供精準的標靶和客製化的治療方案。這些療法可以針對與慢性疾病相關的特定分子路徑、受體或細胞，從而提高療效並減少副作用。此外，慢性病和生活方式相關疾病的負擔越來越重，人們的關注點從緩解症狀轉移到改善疾病和預防，這也推動了市場的成長。

生物技術的各種進步

生物技術大大加速了藥物發現和開發的進程。高通量篩選、組合化學和計算建模等先進技術能夠在更短的時間內識別和測試大量候選藥物。這提高了藥物研發的效率和速度，使生物製藥公司能夠更快地將新療法推向市場。此外，分析個別基因組成、識別疾病標記和了解分子路徑的能力使得針對特定患者群體的標靶治療方法的開發成為可能。基因組學、下一代定序和基因編輯技術等生物技術工具徹底改變了人們對疾病機制的理解，並推動了針對特定基因變異和分子標靶的治療方法的開發，從而推動了市場的發展。

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

第5章：全球生物製藥市場

  • 市場表現及預測
    • 當前表現（2019-2024）
    • 市場預測（2025-2033）
  • COVID-19 的影響
  • 市場：按區域
    • 當前表現（2019-2024）
    • 市場預測（2025-2033）
  • 市場：按適應症
    • 自體免疫疾病
    • 腫瘤學
    • 代謝紊亂
    • 其他
  • 市場：按類別
    • 重組蛋白
      • 當前表現（2019-2024）
      • 市場預測（2025-2033）
    • 單株抗體
      • 當前表現（2019-2024）
      • 市場預測（2025-2033）
    • 純化蛋白質
      • 當前表現（2019-2024）
      • 市場預測（2025-2033）
  • 競爭格局
    • 頂尖生物製藥公司
    • 頂級生物製藥藥物
  • 價值鏈分析
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅

第 6 章：北美

  • 美國
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 加拿大
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）

第 7 章：拉丁美洲

  • 墨西哥
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 巴西
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 阿根廷
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）

第 8 章：歐洲

  • 德國
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 法國
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 義大利
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 西班牙
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 英國
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 俄羅斯
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 土耳其
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）

第 9 章：亞太地區

  • 日本
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 中國
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 澳洲
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 韓國
    • 市場表現（2019-2024）
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 印度
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）
  • 印尼
    • 市場表現（2019-2024）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 主要廠商
    • 市場預測（2025-2033）

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Amgen Inc
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112025A722

The global biopharmaceutical market size reached USD 326.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 664.8 Billion by 2033, exhibiting a growth rate (CAGR) of 8.2% during 2025-2033. The market has been propelled by the increasing prevalence of chronic illnesses, significant advancements in biopharmaceutical, rising government support and healthcare expenditure, personalized medicine and targeted therapies, expansion of biosimilars, and increasing utilization of artificial intelligence and machine learning.

Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs derived from biological sources. They are produced using living organisms, such as bacteria, yeast, or mammalian cells, through biotechnological processes. Unlike traditional small-molecule drugs, which are chemically synthesized, biopharmaceuticals are large, complex molecules that exhibit highly specific interactions with biological targets in the body. They offer several advantages over traditional pharmaceuticals. They tend to be highly specific in their action, often targeting specific receptors or molecules, resulting in increased efficacy and reduced side effects. Additionally, biopharmaceuticals have the potential to treat diseases that were previously challenging to address using conventional drugs.

The market is experiencing significant growth due to the escalating demand for personalized medicine. In addition, the increasing utilization of biopharmaceuticals to treat cancer, diabetes, psoriasis, and rheumatoid arthritis represents another major growth-inducing factor. Besides, the growing awareness among the masses regarding the effectiveness and availability of biopharmaceuticals represents another major growth-inducing factor. Moreover, the rising focus on rare diseases and orphan drugs is driving the growth of the market. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Other than this, governments and regulatory agencies worldwide have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions. Moreover, biopharmaceutical companies are investing in R&D to develop orphan drugs, which target rare diseases, thereby addressing critical medical needs and creating opportunities for market expansion.

Biopharmaceutical Market Trends/Drivers:

The escalating demand for personalized medicine

Personalized medicine has led to a shift toward targeted therapies and precision medicine approaches in the biopharmaceutical market. Biopharmaceutical companies are increasingly focusing on the development of therapies that target specific genetic mutations, biomarkers, or molecular pathways associated with diseases. Moreover, personalized medicine has led to advancements in pharmacogenomics, which is the study of how an individual's genetic makeup influences their response to drugs. Understanding the genetic variations that impact drug metabolism, efficacy, and safety allows for the identification of patients who may be at risk of adverse reactions or those who are more likely to respond favorably to a specific treatment. This knowledge enables biopharmaceutical companies to develop targeted therapies and dosage regimens tailored to individual patients, enhancing treatment effectiveness and reducing the risk of adverse events.

The growing prevalence of chronic and lifestyle-related diseases

Chronic diseases, including cardiovascular disorders, diabetes, cancer, respiratory diseases, and autoimmune conditions, have become major global health challenges. These diseases often have complex underlying mechanisms, requiring targeted and personalized treatment approaches. Biopharmaceuticals, such as monoclonal antibodies, recombinant proteins, and gene therapies, offer precise targeting and tailored treatment options. These therapies can target specific molecular pathways, receptors, or cells associated with chronic diseases, resulting in enhanced efficacy and reduced side effects. Moreover, the increasing burden of chronic and lifestyle-related diseases has shifted the focus from symptomatic relief to disease modification and prevention, which is also propelling the market growth.

Various advancements in biotechnology

Biotechnology has greatly accelerated the drug discovery and development process. Advanced techniques, such as high-throughput screening, combinatorial chemistry, and computational modeling, enable the identification and testing of a large number of drug candidates in a shorter time frame. This has led to an increase in the efficiency and speed of drug discovery, allowing biopharmaceutical companies to bring new therapies to market more rapidly. Besides, the ability to analyze an individual's genetic makeup, identify disease markers, and understand molecular pathways has enabled the development of targeted therapies tailored to specific patient populations. Biotechnology tools, such as genomics, next-generation sequencing, and gene editing techniques, have revolutionized the understanding of disease mechanisms and enabled the development of therapies that address specific genetic variations and molecular targets, thus propelling the market.

Biopharmaceutical Industry Segmentation:

Breakup by Indication:

  • Autoimmune Diseases
  • Oncology
  • Metabolic Disorders
  • Others

Autoimmune diseases represent the leading segment

Autoimmune diseases are often chronic and complex conditions that require long-term management and treatment. These diseases can affect multiple organs and systems in the body, leading to a wide range of symptoms and complications. Biopharmaceutical therapies have shown promising results in managing and controlling autoimmune diseases, providing relief from symptoms, slowing disease progression, and improving quality of life for patients. Therapies, including monoclonal antibodies and other biologics, have emerged as a vital treatment option for autoimmune diseases. They target specific molecules, cells, or pathways involved in the autoimmune response, providing more precise and effective therapeutic interventions.

Breakup by Class:

  • Recombinant Proteins
  • Monoclonal Antibodies
  • Purified Proteins

Monoclonal antibodies exhibit a clear dominance in the market

Monoclonal antibodies are highly specific in targeting disease-specific antigens or cells. They are designed to bind to a specific target with precision, minimizing off-target effects and reducing the risk of adverse reactions. This specificity contributes to their efficacy in treating various diseases, including autoimmune disorders, cancer, inflammatory conditions, and infectious diseases. They also have a wide range of therapeutic applications across different disease areas. They can be used as therapeutic agents on their own or in combination with other treatments. Monoclonal antibodies have been successful in neutralizing pathogens, blocking cell receptors, modulating immune responses, and delivering therapeutic payloads, making them versatile tools for disease management.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Turkey
  • Asia Pacific
  • Japan
  • China
  • Australia
  • South Korea
  • India
  • Indonesia

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Latin America (Mexico, Brazil, and Argentina); Europe (Germany, France, Italy, Spain, the United Kingdom, Russia, and Turkey); and Asia Pacific (Japan, China, Australia, South Korea, India, and Indonesia). According to the report, North America was the largest market for biopharmaceuticals.

North America, particularly the United States, boasts a highly developed healthcare infrastructure, including robust research and development capabilities, advanced clinical facilities, and a strong regulatory framework. The region is home to renowned academic institutions, pharmaceutical companies, and research organizations that drive innovation in the biopharmaceutical industry. The presence of these institutions and infrastructure facilitates the development, manufacturing, and commercialization of biopharmaceutical products. The region has a well-established ecosystem that supports biopharmaceutical innovation, including government funding initiatives, research grants, venture capital investments, and collaborations between academia, industry, and research institutes.

Competitive Landscape:

The competitive landscape of the biopharmaceutical market is highly dynamic and competitive, with numerous global and regional players vying for market share. Nowadays, leading biopharmaceutical companies are heavily investing in R&D to discover and develop innovative therapies. They are conducting preclinical and clinical trials, and advance promising candidates through the regulatory approval process. These investments aim to expand their product pipelines, address unmet medical needs, and stay ahead of competitors in terms of therapeutic advancements. They are also forming strategic partnerships and collaborations with academic institutions, research organizations, and other industry players. These alliances enable them to access new technologies, scientific expertise, and complementary resources.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • Amgen Inc
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A

Recent Developments:

Pfizer and BioNTech developed and distributed their mRNA-based COVID-19 vaccine, Comirnaty (BNT162b2). The vaccine received emergency use authorizations and has been widely deployed globally, playing a crucial role in combating the COVID-19 pandemic.

Amgen Inc. recently received FDA approval for Lumakras (sotorasib), a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations.

AbbVie Inc. has made significant advancements in immunology, particularly with its flagship product, Humira (adalimumab). Humira is one of the world's best-selling biologic drugs used to treat autoimmune conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease.

Key Questions Answered in This Report

  • 1.What was the size of the global biopharmaceutical market in 2024?
  • 2.What is the expected growth rate of the global biopharmaceutical market during 2025-2033?
  • 3.What are the key factors driving the global biopharmaceutical market?
  • 4.What has been the impact of COVID-19 on the global biopharmaceutical market?
  • 5.What is the breakup of the global biopharmaceutical market based on the indication?
  • 6.What is the breakup of the global biopharmaceutical market based on the class?
  • 7.What are the key regions in the global biopharmaceutical market?
  • 8.Who are the key players/companies in the global biopharmaceutical market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

5 Global Biopharmaceutical Market

  • 5.1 Market Performance and Forecast
    • 5.1.1 Current Performance (2019-2024)
    • 5.1.2 Market Forecast (2025-2033)
  • 5.2 Impact of COVID-19
  • 5.3 Market by Region
    • 5.3.1 Current Performance (2019-2024)
    • 5.3.2 Market Forecast (2025-2033)
  • 5.4 Market by Indication
    • 5.4.1 Autoimmune Diseases
    • 5.4.2 Oncology
    • 5.4.3 Metabolic Disorders
    • 5.4.4 Others
  • 5.5 Market by Class
    • 5.5.1 Recombinant Proteins
      • 5.5.1.1 Current Performance (2019-2024)
      • 5.5.1.2 Market Forecast (2025-2033)
    • 5.5.2 Monoclonal Antibodies
      • 5.5.2.1 Current Performance (2019-2024)
      • 5.5.2.2 Market Forecast (2025-2033)
    • 5.5.3 Purified Proteins
      • 5.5.3.1 Current Performance (2019-2024)
      • 5.5.3.2 Market Forecast (2025-2033)
  • 5.6 Competitive Landscape
    • 5.6.1 Top Biopharmaceutical Players
    • 5.6.2 Top Biopharmaceutical Drugs
  • 5.7 Value Chain Analysis
  • 5.8 Porter's Five Forces Analysis
    • 5.8.1 Overview
    • 5.8.2 Bargaining Power of Buyers
    • 5.8.3 Bargaining Power of Suppliers
    • 5.8.4 Degree of Rivalry
    • 5.8.5 Threat of New Entrants
    • 5.8.6 Threat of Substitutes

6 North America

  • 6.1 United States
    • 6.1.1 Market Performance (2019-2024)
    • 6.1.2 Market by Class
      • 6.1.2.1 Recombinant Proteins
      • 6.1.2.2 Monoclonal Antibodies
      • 6.1.2.3 Purified Proteins
    • 6.1.3 Top Players
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Canada
    • 6.2.1 Market Performance (2019-2024)
    • 6.2.2 Market by Class
      • 6.2.2.1 Recombinant Proteins
      • 6.2.2.2 Monoclonal Antibodies
      • 6.2.2.3 Purified Proteins
    • 6.2.3 Top Players
    • 6.2.4 Market Forecast (2025-2033)

7 Latin America

  • 7.1 Mexico
    • 7.1.1 Market Performance (2019-2024)
    • 7.1.2 Market by Class
      • 7.1.2.1 Recombinant Proteins
      • 7.1.2.2 Monoclonal Antibodies
      • 7.1.2.3 Purified Proteins
    • 7.1.3 Top Players
    • 7.1.4 Market Forecast (2025-2033)
  • 7.2 Brazil
    • 7.2.1 Market Performance (2019-2024)
    • 7.2.2 Market by Class
      • 7.2.2.1 Recombinant Proteins
      • 7.2.2.2 Monoclonal Antibodies
      • 7.2.2.3 Purified Proteins
    • 7.2.3 Top Players
    • 7.2.4 Market Forecast (2025-2033)
  • 7.3 Argentina
    • 7.3.1 Market Performance (2019-2024)
    • 7.3.2 Market by Class
      • 7.3.2.1 Recombinant Proteins
      • 7.3.2.2 Monoclonal Antibodies
      • 7.3.2.3 Purified Proteins
    • 7.3.3 Top Players
    • 7.3.4 Market Forecast (2025-2033)

8 Europe

  • 8.1 Germany
    • 8.1.1 Market Performance (2019-2024)
    • 8.1.2 Market by Class
      • 8.1.2.1 Recombinant Proteins
      • 8.1.2.2 Monoclonal Antibodies
      • 8.1.2.3 Purified Proteins
    • 8.1.3 Top Players
    • 8.1.4 Market Forecast (2025-2033)
  • 8.2 France
    • 8.2.1 Market Performance (2019-2024)
    • 8.2.2 Market by Class
      • 8.2.2.1 Recombinant Proteins
      • 8.2.2.2 Monoclonal Antibodies
      • 8.2.2.3 Purified Proteins
    • 8.2.3 Top Players
    • 8.2.4 Market Forecast (2025-2033)
  • 8.3 Italy
    • 8.3.1 Market Performance (2019-2024)
    • 8.3.2 Market by Class
      • 8.3.2.1 Recombinant Proteins
      • 8.3.2.2 Monoclonal Antibodies
      • 8.3.2.3 Purified Proteins
    • 8.3.3 Top Players
    • 8.3.4 Market Forecast (2025-2033)
  • 8.4 Spain
    • 8.4.1 Market Performance (2019-2024)
    • 8.4.2 Market by Class
      • 8.4.2.1 Recombinant Proteins
      • 8.4.2.2 Monoclonal Antibodies
      • 8.4.2.3 Purified Proteins
    • 8.4.3 Top Players
    • 8.4.4 Market Forecast (2025-2033)
  • 8.5 United Kingdom
    • 8.5.1 Market Performance (2019-2024)
    • 8.5.2 Market by Class
      • 8.5.2.1 Recombinant Proteins
      • 8.5.2.2 Monoclonal Antibodies
      • 8.5.2.3 Purified Proteins
    • 8.5.3 Top Players
    • 8.5.4 Market Forecast (2025-2033)
  • 8.6 Russia
    • 8.6.1 Market Performance (2019-2024)
    • 8.6.2 Market by Class
      • 8.6.2.1 Recombinant Proteins
      • 8.6.2.2 Monoclonal Antibodies
      • 8.6.2.3 Purified Proteins
    • 8.6.3 Top Players
    • 8.6.4 Market Forecast (2025-2033)
  • 8.7 Turkey
    • 8.7.1 Market Performance (2019-2024)
    • 8.7.2 Market by Class
      • 8.7.2.1 Recombinant Proteins
      • 8.7.2.2 Monoclonal Antibodies
      • 8.7.2.3 Purified Proteins
    • 8.7.3 Top Players
    • 8.7.4 Market Forecast (2025-2033)

9 Asia Pacific

  • 9.1 Japan
    • 9.1.1 Market Performance (2019-2024)
    • 9.1.2 Market by Class
      • 9.1.2.1 Recombinant Proteins
      • 9.1.2.2 Monoclonal Antibodies
      • 9.1.2.3 Purified Proteins
    • 9.1.3 Top Players
    • 9.1.4 Market Forecast (2025-2033)
  • 9.2 China
    • 9.2.1 Market Performance (2019-2024)
    • 9.2.2 Market by Class
      • 9.2.2.1 Recombinant Proteins
      • 9.2.2.2 Monoclonal Antibodies
      • 9.2.2.3 Purified Proteins
    • 9.2.3 Top Players
    • 9.2.4 Market Forecast (2025-2033)
  • 9.3 Australia
    • 9.3.1 Market Performance (2019-2024)
    • 9.3.2 Market by Class
      • 9.3.2.1 Recombinant Proteins
      • 9.3.2.2 Monoclonal Antibodies
      • 9.3.2.3 Purified Proteins
    • 9.3.3 Top Players
    • 9.3.4 Market Forecast (2025-2033)
  • 9.4 South Korea
    • 9.4.1 Market Performance (2019-2024)
      • 9.4.1.1 Recombinant Proteins
      • 9.4.1.2 Monoclonal Antibodies
      • 9.4.1.3 Purified Proteins
    • 9.4.2 Top Players
    • 9.4.3 Market Forecast (2025-2033)
  • 9.5 India
    • 9.5.1 Market Performance (2019-2024)
    • 9.5.2 Market by Class
      • 9.5.2.1 Recombinant Proteins
      • 9.5.2.2 Monoclonal Antibodies
      • 9.5.2.3 Purified Proteins
    • 9.5.3 Top Players
    • 9.5.4 Market Forecast (2025-2033)
  • 9.6 Indonesia
    • 9.6.1 Market Performance (2019-2024)
    • 9.6.2 Market by Class
      • 9.6.2.1 Recombinant Proteins
      • 9.6.2.2 Monoclonal Antibodies
      • 9.6.2.3 Purified Proteins
    • 9.6.3 Top Players
    • 9.6.4 Market Forecast (2025-2033)

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Competitive Landscape

  • 11.1 Market Structure
  • 11.2 Key Players
  • 11.3 Profiles of Key Players
    • 11.3.1 AbbVie Inc.
    • 11.3.2 Amgen Inc
    • 11.3.3 Biogen Inc.
    • 11.3.4 Eli Lilly and Company
    • 11.3.5 F. Hoffmann-La Roche AG
    • 11.3.6 Johnson & Johnson
    • 11.3.7 Merck & Co. Inc.
    • 11.3.8 Novo Nordisk A/S
    • 11.3.9 Pfizer Inc.
    • 11.3.10 Sanofi S.A

List of Figures

  • Figure 1: Global: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 2: Complexity of Biopharmaceuticals
  • Figure 3: Sources of Biopharmaceuticals
  • Figure 4: Global: Biopharmaceutical Market: Value Trends (in Billion USD), 2019-2024
  • Figure 5: Global: Biopharmaceutical Market Forecast: Value Trends (in Billion USD), 2025-2033
  • Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2024
  • Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2033
  • Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2024
  • Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million USD), 2025-2033
  • Figure 11: Global: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 13: Global: Recombinant Proteins Market Forecast (in Million USD), 2025-2033
  • Figure 14: Global: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million USD), 2025-2033
  • Figure 17: Global: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 19: Global: Purified Proteins Market Forecast (in Million USD), 2025-2033
  • Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %)
  • Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
  • Figure 22: Global: Biopharmaceutical Industry: Porter's Five Forces Analysis
  • Figure 23: United States: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 25: United States: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 27: United States: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 29: United States: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 32: United States: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 34: Canada: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 36: Canada: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 38: Canada: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 41: Canada: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 43: Mexico: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 45: Mexico: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 47: Mexico: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 49: Mexico: Purified Proteins Market (in '000 USD), 2019-2024
  • Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 53: Brazil: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 55: Brazil: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 57: Brazil: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 59: Brazil: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 63: Argentina: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 65: Argentina: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 67: Argentina: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 69: Argentina: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 73: Germany: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 75: Germany: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 77: Germany: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 79: Germany: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 82: Germany: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 84: France: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 86: France: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 88: France: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 90: France: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 92: France: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 94: Italy: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 96: Italy: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 98: Italy: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 100: Italy: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 102: Italy: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 104: Spain: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 106: Spain: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 108: Spain: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 110: Spain: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 113: Spain: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 115: UK: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 117: UK: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 119: UK: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 121: UK: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 124: UK: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 126: Russia: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 128: Russia: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 130: Russia: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 132: Russia: Purified Proteins Market: (in Million USD), 2019-2024
  • Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 135: Russia: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 137: Turkey: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 139: Turkey: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 142: Turkey: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 146: Japan: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 148: Japan: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 150: Japan: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 152: Japan: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 154: Japan: Biopharmaceutical Market Forecast: Value trend (in Million USD), 2025-2033
  • Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 156: China: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 158: China: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 160: China: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 162: China: Purified Proteins Market: (in Million USD), 2019-2024
  • Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 165: China: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 167: Australia: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 169: Australia: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 171: Australia: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 173: Australia: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 175: Australia: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 177: South Korea: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 179: South Korea: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 181: South Korea: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2024
  • Figure 183: South Korea: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 188: India: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 190: India: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 192: India: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 193: India: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 195: India: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 197: Indonesia: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 199: Indonesia: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 201: Indonesia: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2022
  • Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
  • Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
  • Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
  • Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in USD)
  • Figure 211: Emerging Biopharmaceutical Market Forecast (in Million USD), 2024 & 2033
  • Figure 212: Developed Biopharmaceutical Market Forecast (in Million USD), 2024 & 2033
  • Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2022
  • Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million USD)
  • Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)

List of Tables

  • Table 1: Global: Biopharmaceutical Market: Definition & Segmentation
  • Table 2: Global: Biopharmaceutical Market: SWOT Analysis
  • Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (in Million USD), 2024 & 2033
  • Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals
  • Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
  • Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million USD), 2019-2024
  • Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million USD), 2025-2033
  • Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion USD), 2024
  • Table 9: Mode of Administration of Popular Biotech Drugs